Global Multiple Sclerosis Therapeutics Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: July 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Multiple Sclerosis Therapeutics Market was valued at $30.0 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 5.2% CAGR, to an estimated market size of $38.7 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global Multiple Sclerosis (MS) therapeutics market includes disease-modifying therapies (DMTs), monoclonal antibodies, and symptomatic treatments designed to manage the chronic autoimmune disorder of the central nervous system.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Multiple Sclerosis Therapeutics Market in the period 2025-30:
- The market is experiencing a significant shift toward high-efficacy therapies, particularly anti-CD20 monoclonal antibodies, which are displacing older interferon treatments.
- A robust clinical pipeline is increasingly focused on Bruton’s Tyrosine Kinase (BTK) inhibitors to provide effective oral alternatives for both relapsing and progressive forms of the disease.
- There is a growing emphasis on neuroprotection and remyelination research to address the underlying nerve damage and long-term disability associated with progressive MS.
- The introduction of biosimilars and generic formulations for blockbuster drugs is increasing treatment accessibility while pressuring the profit margins of branded manufacturers.
- Patient-centric delivery methods, such as oral medications and subcutaneous autoinjectors, are becoming the standard to improve treatment adherence and convenience.
- Artificial Intelligence (AI) and digital health tools are being integrated into clinical practice to enhance early diagnosis, monitor disease progression, and personalize therapeutic regimens.
- Real-world evidence and outcomes-based reimbursement models are increasingly influencing payer decisions and the commercial success of new MS therapies.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Oral Therapies
- Injectable Therapies
- Infusion Therapies